Protara Therapeutics (NASDAQ: TARA) — Perfil da empresa, notícias e dados financeiros
Protara Therapeutics develops therapies for rare diseases, focusing on unmet medical needs and improving patient outcomes.
Protara Therapeutics
Protara Therapeutics (NASDAQ:TARA) focuses on identifying and advancing transformative therapies for people afflicted with rare and specialty diseases. Their innovative approach aims at developing treatments that can offer significant improvements over existing therapies, primarily concentrating on unmet medical needs. Projects span a range of conditions, with their pipeline including both in-development drugs and potential new therapeutic avenues exploring cutting-edge scientific advances. Objectives are not just limited to drug development but also encompass broadening access to groundbreaking treatments for patients who currently have limited options, underlining Protara's commitment to enhancing health outcomes and ultimately improving quality of life for those they serve.
Resumo
Operações
Produtos e/ou serviços de Protara Therapeutics
- TARA-002, an investigational therapy derived from the OK-432 strain of Streptococcus pyogenes, is designed for the treatment of lymphatic malformations, a rare, non-malignant condition.
- Development of advanced drug formulations designed to improve efficacy and reduce side effects for patients with severe medical conditions.
- Collaboration with academic and research institutions to discover and develop next-generation treatments for cancer and rare diseases.
- Engagement in clinical trials to ensure the safety and efficacy of their therapies, aiming to meet the stringent requirements of regulatory bodies.
equipe executiva do Protara Therapeutics
- Jesse SheffermanCo-founder, CEO, President & Director
- Jacqueline ZummoCo-Founder, Chief R&D Officer
- Patrick FabbioChief Financial Officer
- Hannah FryVP, Principal Accounting Officer & Controller
- Justine O'MalleySenior Vice President of Investor Relations & Corporate Affairs
- Mary J. GrendellGeneral Counsel & Corporate Secretary
- Shane WilliamsChief People Officer
- William ConklingChief Commercial Officer
- Carla BeckhamLead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist
- Neal D. ShoreMedical Director of START Carolinas/ Carolina Urologic Research Center
Últimas notícias sobre a Protara Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Protara Therapeutics, em USD.
- Cap. de mercado
- 147,1 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -64,5 mi | -57,4 mi | |
| 0 | -49,2 mi | -44,6 mi | |
| 0 | -43,6 mi | -40,4 mi | |
| 0 | -67,1 mi | -66 mi |